NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing combined neuroplastic treatments using D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with support from Chief Medical Innovation Officer Dr. Joshua Brown, and aims to pursue non-dilutive government and institutional funding while developing deployable solutions for military and first responder use, including a prototype in partnership with Zeta Surgical Inc. expected to be unveiled at the Clinical TMS Society annual meeting in June 2026.
To view the full press release, visit https://ibn.fm/LmoQY
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP
About DefenseWireNews
DefenseWireNews (“DWN”) is a specialized communications platform with a focus on defense contractors, aerospace firms, cybersecurity leaders, advanced manufacturing innovators, and other mission-critical companies operating at the intersection of public markets and government demand. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, DWN is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, DWN brings its clients unparalleled recognition and brand awareness. DWN is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from DefenseWireNews, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.DefenseWireNews.com Please see full terms of use and disclaimers on the DefenseWireNews website applicable to all content provided by DWN, wherever published or re-published: https://www.DefenseWireNews.com/Disclaimer
DefenseWireNews
Austin, TX
www.DefenseWireNews.com
512.354.7000 Office
Editor@DefenseWireNews.com
DefenseWireNews is powered by IBN
